Vivolta
- Company typePrivate
- Founded2008
- HeadquartersWaalre, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
Vivolta firmographics
Firmographics- Name
- Vivolta
- Legal name
- Vivolta B.V.
- Website
- https://vivolta.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Vivolta industry classification
Industry- Product category
- Medical Device Contract Manufacturing
- NAICS
- Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where Vivolta is headquartered
LocationHeadquarters
- HQ city
- Waalre
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
Vivolta business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing (CDMO): VIVOLTA provides full-suite CDMO services spanning from concept development to commercial manufacturing. Services include feasibility testing, product & process development, process validation & scale-up, and clinical & commercial manufacturing. The company consolidates clients' supply chains into a one-stop-shop for electrospun medical products and components, managing raw material vendors and integrating post-processes such as laser cutting, packaging, and labelling.
- Electrospinning Equipment Sales: VIVOLTA sells EC-CLI climate-controlled electrospinning R&D platforms to academic research institutes and companies globally. Over 120 IME electrospinning R&D platforms have been sold and distributed across six continents.
- Development Services: Concept creation, feasibility testing, and product & process development services for medical device companies developing electrospun products.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Vivolta product offering
Product offeringCore offering
Vivolta is a fully integrated contract development and manufacturing organization (CDMO) that develops, validates, and manufactures electrospun medical products and components on its proprietary MediSpin™ automated production platform. Its services span concept creation, feasibility testing, product and process development, process validation and scale-up, and clinical and commercial manufacturing for cardiovascular, orthopaedic, wound care, drug delivery, dental, neurosurgery, and ENT applications. The company also sells EC-CLI climate-controlled electrospinning R&D systems to academic and corporate research users worldwide.
Product overview
VIVOLTA is a fully integrated contract development and manufacturing organization (CDMO) specializing in electrospinning for the medical device industry. The company offers the MediSpin™ Platform as its core production technology—the world's first fully automated medical electrospinning production system—and the EC-CLI Platform for R&D purposes. VIVOLTA provides a full suite of CDMO services spanning from concept development to commercial manufacturing, including add-on modules for the EC-CLI such as the EM-ASM Anti-Statics Module, EM-GSM Gas Shield Module, EM-TMM Thickness Measurement Module, EM-RDC Rotating Drum Collector, and EM-CAX Coaxial Nozzle. The company manufactures various electrospun medical products and components for applications including cardiovascular, orthopaedic, wound healing, and drug delivery.
Differentiator
Problem solved
Functional benefit
Products and services
- MediSpin™ Production Platform The world's first and only fully automated, scalable medical electrospinning production platform, used by Vivolta to manufacture electrospun medical products and components at commercial scale with real-time sensor-controlled parameters and 100% in-line quality verification.
- EC-CLI Electrospinning R&D System Climate-controlled electrospinning R&D system with ±0.5°C and ±2% RH accuracy and modular plug-and-play add-ons, sold to academic and corporate research users globally for reproducible prototyping and process development.
- Contract Development Services Full-service CDMO development offerings including concept creation, feasibility testing, and product and process development for medical device companies targeting electrospun implants and regenerative products.
- Contract Manufacturing Services Clinical and commercial production services for electrospun medical products including process validation, scale-up, supply chain management, and integration of post-processes such as laser cutting, packaging, and labelling.
- SimplySilk® Membrane Manufacturing Exclusive contract manufacturing of Fibrothelium's CE-marked Class III SimplySilk® resorbable barrier membrane for guided bone regeneration in dental implants, periodontal procedures, and cranio-maxillo-facial surgery, produced on MediSpin™ at commercial scale.
- Neurochase Micro-Catheter Manufacturing Exclusive component manufacturing of Neurochase's electrospun micro-catheters for delivering advanced CNS therapies to the brain via convection enhanced delivery (CED), using MediSpin™ at scale.
Quantifiable outcome
- Fiber diameter deviation below 5% year-round with climate-sealed chambers holding ±0.5°C and ±1% relative humidity
- +4 more outcomes
Companies that use Vivolta
Customer profileNamed customers2 records
Segments8 records
Ideal customer profiles2 records
Vivolta technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Vivolta partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and strategic.
- Fibrothelium GmbHcoreVIVOLTA signed a long-term partnership with Fibrothelium, a specialist in silk protein biomaterials, to exclusively manufacture electrospun components for Fibrothelium's SimplySilk® membrane - an advanced electrospun silk membrane for guided bone regeneration (GBR) in oral surgery. VIVOLTA leverages its fully automated MediSpin™ technology to produce the electrospun membranes at commercial scale while ensuring consistent quality and regulatory compliance. SimplySilk® membrane is a CE-marked Class III medical device commercially available in Europe, with FDA submission targeted for 2027.
- NeurochasecoreVIVOLTA signed a long-term partnership with Neurochase, a CNS delivery platform specialist, to manufacture electrospun micro-catheters for delivering advanced therapies to the brain via Convection Enhanced Delivery (CED). VIVOLTA first partnered with Neurochase in 2022 and has worked as part of Neurochase's R&D team, bringing material science and application development expertise. VIVOLTA will be Neurochase's exclusive component manufacturer based on its ability to manufacture electrospun medical products at scale using MediSpin™. Neurochase plans clinical trials in 2025.
- AvelostrategicVIVOLTA, Avelo, and BLINK consortium awarded €1.5M Eurostars grant (BreathCounts project) to develop a diagnostic system for lower respiratory tract infections. VIVOLTA contributes electrospun filter technology for a disposable breath collection device. The project aims for market launch in 2027 with the world's first breath-based system for fast, accurate diagnosis of LRTIs.
- BLINKstrategicVIVOLTA, Avelo, and BLINK consortium awarded €1.5M Eurostars grant (BreathCounts project) to develop diagnostic system for lower respiratory tract infections using breath analysis technology combined with VIVOLTA's electrospun filter.
- Dutch Research Council (NWO)strategicVIVOLTA awarded NWO grant along with collaborators Delft University, DSM, and Meatable for Project SUSTAINER investigating feasibility of electrospinning natural and synthetic structural proteins for sustainable food and biomedical applications. Grant of €1 million as part of NWO's Open Technology Programme, running for five years.
- STENTiTstrategicVIVOLTA, STENTiT, and Corbion announced collaboration to develop an electrospun, regenerative stent for clinical use, initially focused on treatment of patients suffering from critical limb ischemia. The consortium aims to manufacture batches of clinical-grade stents together. The regenerative stent uses bioresorbable nanofibers that allow influx of circulating blood cells, triggering natural healing response for vascular regeneration, then safely resorbs over time.
- CorbionstrategicVIVOLTA, STENTiT, and Corbion collaboration to develop regenerative stent for critical limb ischemia treatment. Corbion provides bioresorbable materials expertise as part of the Dutch Smart BioMaterials Consortium (SBMC).
Scale indicators10 records
Recent moves2 records
Vivolta competitors and assessment
Company assessmentDirect peers
- Polyganics: Dutch regenerative medicine company developing bioresorbable medical devices including dural and nerve repair products. Comparable electrospun/biopolymer device focus; Rudy Mareel (VIVOLTA Chairman) previously led Polyganics to its Regenity acquisition.
- The Electrospinning Company: UK-based electrospinning specialist offering contract manufacturing and equipment for biomedical applications. Most directly comparable to VIVOLTA's MediSpin and EC-CLI offerings; Jeff Orosco joined VIVOLTA from this company.
- STENTiT: Dutch medical device company developing bioresorbable electrospun regenerative stents. Active VIVOLTA partner (critical limb ischemia program) and overlaps directly on electrospun vascular scaffold technology.
- Mediliant: Swiss medical device CDMO where VIVOLTA CEO Denis Leissing previously served as CEO. Directly comparable as a specialized medical device contract development and manufacturing organization serving implant and combination product clients.
Emerging players
- CollPlant Biotechnologies: Israel-based regenerative medicine company using plant-derived recombinant human collagen for tissue repair and 3D bioprinting. Comparable in ECM-mimicking biomaterials for soft tissue, orthopaedic, and wound healing applications.
- Tissium: French medtech developing programmable tissue adhesives and polymers for tissue reconstruction and drug delivery. Comparable in next-generation polymer-based platforms for cardiovascular and general surgery applications.
- Xeltis: Dutch clinical-stage company developing bioabsorbable restorative cardiovascular devices using supramolecular polymers. Comparable in regenerative vascular implant focus and Dutch high-tech medical device ecosystem positioning.
Broad incumbents
- DSM Biomedical: Dutch biomedical materials leader supplying bioresorbable polymers, coatings, and drug delivery technologies to medical device manufacturers. Jeff Orosco previously worked at DSM Biomedical; comparable as a Dutch biomaterials partner/incumbent in VIVOLTA's supplier network.
- Regenity Biosciences: US-based regenerative medicine company that acquired Polyganics. Broader portfolio of regenerative devices across dural repair, nerve regeneration, and ENT — overlaps with VIVOLTA's neurosurgery and ENT target segments.
Others
- Corbion: Dutch supplier of bioresorbable polymers and lactic acid-based materials for medical devices. Strategic partner in the STENTiT regenerative stent consortium; comparable as an enabling materials provider to electrospun implant manufacturers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat1 record
Key risks6 records
Key highlights7 records
Customer concentration
Vivolta social profiles
Digital presenceVivolta compliance and trust
Trust signalCompliance1 record
Vivolta financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vivolta leadership team
Management profileNumber of profiles
Profiles13 records
Vivolta funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vivolta M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vivolta
What does Vivolta do?
Vivolta is a fully integrated contract development and manufacturing organization (CDMO) that develops, validates, and manufactures electrospun medical products and components on its proprietary MediSpin™ automated production platform. Its services span concept creation, feasibility testing, product and process development, process validation and scale-up, and clinical and commercial manufacturing for cardiovascular, orthopaedic, wound care, drug delivery, dental, neurosurgery, and ENT applications. The company also sells EC-CLI climate-controlled electrospinning R&D systems to academic and corporate research users worldwide.
Is Vivolta a public or private company?
Vivolta is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vivolta founded?
Vivolta was founded in 2008. It employs 11 to 50 people.
Where is Vivolta based?
Vivolta is headquartered in Waalre, Netherlands, in the Europe region.
How does Vivolta make money?
Three revenue lines are on record. Contract Development and Manufacturing (CDMO) is the primary driver. The others are electrospinning Equipment Sales and development Services.
Who are Vivolta's main competitors?
Direct peers on record are Polyganics, The Electrospinning Company, STENTiT and Mediliant. Emerging players are CollPlant Biotechnologies, Tissium and Xeltis. Broad incumbents are DSM Biomedical and Regenity Biosciences. Corbion is listed as an others.
Does Vivolta have an API?
No public API is recorded for Vivolta.
What industry is Vivolta in?
Vivolta's product category is Medical Device Contract Manufacturing. Its primary akta.pro industry code is HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 5417 and its SIC code is 8731.